Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Angela Combs

Nurse Practitioner, Psychiatric/Mental Health Richland, WA Nurse Practitioner

NPI 1093119232 CMS profile 11005376

1201 Jadwin Ave Ste 102, Richland, WA 99352

Open in the dashboard

General payments

$120,606

496 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Angela Combs of Richland, WA is reported in the CMS Open Payments database as having received $120,606 across 496 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,058 18
2024 General $7,421 35
2023 General $36,306 181
2022 General $72,023 195
2021 General $3,798 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Angela Combs
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Angela Combs were reported at $1,058. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Angela Combs Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $3,798 $166 $54–$482 $132
2022 $72,023 $195 $66–$559 $149
2023 $36,306 $233 $82–$673 $160
2024 $7,421 $236 $84–$688 $164
2025 $1,058 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Neurocrine Biosciences, Inc. $86,500 152 payments
  2. Teva Pharmaceuticals USA, Inc. $18,770 61 payments
  3. Alkermes, Inc. $9,182 44 payments
  4. Janssen Pharmaceuticals, Inc $1,079 53 payments
  5. Axsome Therapeutics, Inc. $903 24 payments
  6. ITI, Inc. $871 35 payments
  7. AbbVie, Inc. $604 19 payments
  8. Sunovion Pharmaceuticals Inc. $519 34 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $439 21 payments
  10. Otsuka America Pharmaceutical, Inc. $437 12 payments
  11. Other $1,302 41 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $68,239 33 payments
  2. Consulting Fee $20,588 6 payments
  3. Travel and Lodging $19,720 67 payments
  4. Food and Beverage $11,980 388 payments
  5. Education $79 2 payments
Products named General payments · program years 2021–2025
  1. INGREZZA $86,343 147 payments
  2. AUSTEDO $15,560 45 payments
  3. LYBALVI Cns $8,697 36 payments
  4. LYBALVI Cns $8,614 32 payments
  5. LYBALVI Cns $8,564 25 payments
  6. LYBALVI Cns $8,564 25 payments
  7. Austedo XR $3,181 15 payments
  8. Auvelity $903 24 payments
  9. CAPLYTA $698 30 payments
  10. INVEGA SUSTENNA $648 44 payments
  11. Other $5,798 202 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

583

Median for Nurse Practitioner: 389

Drug cost

$81,527

Median for Nurse Practitioner: $21,885

Branded share of claims

22.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 24 $37,756
Auvelity Dextromethorphan Hbr/Bupropion Brand 12 $13,520
Dayvigo Lemborexant Brand 26 $8,636
Lisdexamfetamine Dimesylate Generic 25 $6,043
Trintellix Vortioxetine Hydrobromide Brand 11 $4,815
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 25 $3,092
Ziprasidone Hcl Generic 14 $1,234
Buspirone Hcl Generic 62 $958
Lurasidone Hcl Generic 14 $787
Duloxetine Hcl Generic 23 $784

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$2,230

Medicare's payments for the services billed

Medicare patients

16

Average age 63

Services billed

33

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
  • Neurocrine Biosciences, Inc. $6,855
$6,855 — —
CAPLYTA
  • ITI, Inc. $183
$183 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $146
$146 — —
VRAYLAR
  • AbbVie, Inc. $62
$62 24 —
Auvelity
  • Axsome Therapeutics, Inc. $54
$54 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

496 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record